Loading
Mitchell Schnall is the radiologist who brought imaging research into the ECOG-ACRIN cooperative group.
Mitchell Schnall is Group Co-Chair of the ECOG-ACRIN Cancer Research Group and Chair of Radiology at the University of Pennsylvania, within the Abramson Cancer Center. A radiologist and former ACRIN network chair specialising in breast MRI and imaging trials, he brought imaging research into the cooperative group and led multicentre trials of breast MRI and imaging biomarkers, including the TMIST tomosynthesis screening trial. His papers include the New England Journal of Medicine study of MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer and a Radiology multicentre study of diagnostic architectural and dynamic features at breast MR imaging. His work spans MRI, mammography and tomosynthesis, and PET/CT.
| Title | Journal | Year |
|---|---|---|
| MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer | New England Journal of Medicine | 2007 |
| Diagnostic architectural and dynamic features at breast MR imaging: multicenter study | Radiology | 2006 |
Shares ECOG-ACRIN Cancer Research Group, Mammography & tomosynthesis, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
Shares Mammography & tomosynthesis, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
Shares Mammography & tomosynthesis, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
Shares Abramson Cancer Center, University of Pennsylvania, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
Shares ECOG-ACRIN Cancer Research Group, Abramson Cancer Center, University of Pennsylvania.
Shares Mammography & tomosynthesis, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
Shares Mammography & tomosynthesis, MRI, HR-positive / HER2-negative breast cancer.
Shares Mammography & tomosynthesis, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.